About RethinkPeptides

Who We Are

RethinkPeptides is an independent peptide science education platform. We are not anti-peptide. We are not pro-peptide. We are pro-evidence.

Founded in 2026, RethinkPeptides exists because the public conversation about peptides is fragmented. The supplement industry tells you peptides are miracle compounds. Skeptics dismiss them entirely. Neither is giving you the full picture. We exist to fill that gap with peer-reviewed evidence, transparent methodology, and editorial independence.

RethinkPeptides is not affiliated with any peptide company, supplement brand, advocacy group, government agency, or trade organization. We are an independent editorial operation with a single mission: give people the science they need to make informed decisions.

Our Expertise

RethinkPeptides content is produced by the RethinkPeptides Research Team — a dedicated editorial operation focused exclusively on translating peptide science into accessible, accurate public health education. Our editorial process involves systematic literature review across four core domains:

• Pharmacology — peptide pharmacokinetics, bioavailability, receptor binding dynamics, dosing protocols, and drug interaction profiles
• Endocrinology — growth hormone secretagogues, GnRH analogs, insulin peptides, thymosin peptides, and hormonal modulation research
• Neuroscience — neuropeptides, nootropic peptides, neuroprotection, and cognitive enhancement research
• Public health — safety profiles, regulatory considerations, contamination risks, quality control, and vulnerable population considerations

Our systematic literature review draws from journals including JAMA, JAMA Network Open, The Lancet, New England Journal of Medicine, Endocrinology, Journal of Clinical Endocrinology & Metabolism, Peptides, Journal of Peptide Science, PLOS ONE, and Current Pharmaceutical Design.

Our Database

RethinkPeptides maintains a comprehensive publicly accessible peptide research database. Every study in our database is tagged, rated for evidence strength, classified by study type, and linked to relevant articles. Our research database is freely accessible and searchable by topic, evidence strength, and study type. Read more about our evidence methodology.

Editorial Independence

Our credibility depends on our independence. We guard it carefully.

• No peptide industry funding. We do not accept funding, grants, sponsorships, or financial support of any kind from peptide companies, supplement brands, or peptide-adjacent businesses.
• No peptide advertising. We do not display advertisements from peptide companies or supplement brands. We do not accept sponsored content.
• No affiliate relationships. We do not earn commissions or referral fees from any peptide product or related service. We have no affiliate links.
• Evidence-driven content. Every editorial decision is driven by the research. We cover both the potential benefits and the documented risks of peptide use with equal rigor and transparency.

Our Methodology

Every article published on RethinkPeptides follows a multi-stage editorial pipeline designed to meet the highest standards of health science communication:

1. Research and source identification. Systematic literature review across PubMed, Google Scholar, and journal databases. Relevant studies pulled from our verified citation library.
2. Drafting with inline citations. Articles composed with every factual claim tied to a named, verifiable source during the writing process — not added after the fact.
3. Scientific accuracy review. All claims cross-referenced against original source studies. Numbers, percentages, sample sizes, and methodology descriptions verified for accuracy.
4. Preflight verification. Automated checks confirm formatting consistency, metadata completeness, structural integrity, and schema validation.
5. Publication with version tracking. Every article published with both datePublished and dateModified timestamps. All substantive changes reflected in modification dates.

Evidence strength is rated transparently using a three-tier system: well-established, moderate, and preliminary. Study limitations are always noted. When the evidence is mixed or uncertain, we say so. Read the full details in our evidence methodology and editorial policy.

What Makes Us Different

We are neither pro-peptide nor anti-peptide. We are pro-evidence.

• We do not cherry-pick studies that support a particular viewpoint. When a finding supports peptide benefits, we report it. When a finding identifies risks, we report that too.
• We do not use phrases like “studies show” without naming the specific study. Every claim names author(s), year, and journal.
• We distinguish between well-established findings and preliminary research. We do not present single pilot studies as settled science.
• We report honest uncertainty. When we do not know something, we say “the research has not established this” rather than speculating.
• Our research database is freely accessible. You can verify every claim we make by looking up the named study yourself.

Corrections and Accountability

We welcome corrections. If you find an error in any article or study summary — a misquoted statistic, an outdated finding, a broken source reference, or any other inaccuracy — we want to know about it.

• Email corrections to corrections@rethinkpeptides.com
• We review all submissions and respond within 7 days
• All corrections are logged with transparent versioning
• Every article displays both datePublished and dateModified
• We do not silently alter published content — substantive changes are always reflected in the modification date

What We Cover

Our articles and research pillars span the full spectrum of peptide science:

• Therapeutic peptides — BPC-157, TB-500, GHK-Cu, and other peptides used in healing, recovery, and tissue repair research
• Growth hormone secretagogues — what the evidence actually supports for ipamorelin, CJC-1295, sermorelin, and related compounds
• Safety and quality — contamination risks, purity testing, sourcing considerations, and regulatory landscape
• Neuropeptides — selank, semax, and other peptides studied for cognitive and neurological effects
• Pharmacology — how peptides interact with biological systems, bioavailability, dosing research, and metabolism
• Drug interactions — peptide-medication interactions and combination risk profiles
• Specific populations — age considerations, contraindications, and population-specific research

Get in Touch

Have a question, correction, or topic suggestion? We would love to hear from you.

• General inquiries: hello@rethinkpeptides.com
• Corrections and error reports: corrections@rethinkpeptides.com

Medical Disclaimer

RethinkPeptides provides educational content only. Nothing on this site constitutes medical advice, diagnosis, or treatment. We are not a healthcare provider and do not provide clinical services. Always consult a qualified healthcare provider before making decisions about peptide use, particularly if you have a medical condition or take prescription medications. Read our full medical disclaimer.